Monday, April 30, 2018

BRIEF-Regeneron Says FDA To Conduct Priority Review Of Cemiplimab As A Potential Treatment For Advanced Cutaneous Squamous Cell Carcinoma

* FDA TO CONDUCT PRIORITY REVIEW OF CEMIPLIMAB AS A POTENTIAL TREATMENT FOR ADVANCED CUTANEOUS SQUAMOUS CELL CARCINOMA
Posted by at

No comments:

Post a Comment

Subscribe to: Post Comments (Atom)